title: Haemolytic anaemia after oral artemether-lumefantrine treatment in a patient affected by severe imported falciparum malaria.
abstract: Artemisinin and its derivatives are essential components of artemisinin-based combination therapies for treating severe falciparum malaria. In this paper, we describe the occurrence of haemolysis after oral artemether-lumefantrine treatment. To the best of our knowledge, this is the second reported case of a patient affected by severe falciparum malaria with haemolytic anaemia that is likely associated with oral artemether-lumefantrine treatment.
authors.affiliation: Lazzaro Spallanzani, National Institute for Infectious Diseases-IRCCS, Via Portuense 292, 00179, Rome, Italy. dr.pasqualedenardo@gmail.com
authors.forename: P
authors.initials: P
authors.lastname: De Nardo
authors.forename: A
authors.initials: A
authors.lastname: Oliva
authors.forename: M L
authors.initials: ML
authors.lastname: Giancola
authors.forename: P
authors.initials: P
authors.lastname: Ghirga
authors.forename: P
authors.initials: P
authors.lastname: Mencarini
authors.forename: M
authors.initials: M
authors.lastname: Bibas
authors.forename: E
authors.initials: E
authors.lastname: Nicastri
authors.forename: A
authors.initials: A
authors.lastname: Antinori
authors.forename: A
authors.initials: A
authors.lastname: Corpolongo
mesh_terms: D000284:Administration, Oral; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D000962:Antimalarials / Q000008:administration & dosage / Q000009:adverse effects*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000008:administration & dosage / Q000009:adverse effects*; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects*; D005449:Fluorenes / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes
references.citation: Malar J. 2012 Mar 31;11:102
references.pmid: 22462806
references.citation: Pak J Pharm Sci. 2012 Oct;25(4):851-5
references.pmid: 23010004
references.citation: Emerg Infect Dis. 2011 May;17(5):771-7
references.pmid: 21529383
references.citation: Malar J. 2012 May 17;11:169
references.pmid: 22594446
references.citation: Kansenshogaku Zasshi. 2001 Sep;75(9):822-5
references.pmid: 11605194
references.citation: Am J Trop Med Hyg. 2012 Jul;87(1):50-56
references.pmid: 22764291
references.citation: Malar J. 2012 Mar 27;11:91
references.pmid: 22453057
references.citation: Blood Rev. 2010 Jul-Sep;24(4-5):143-50
references.pmid: 20650555
references.citation: Kansenshogaku Zasshi. 2002 Oct;76(10):888-92
references.pmid: 12448849
references.citation: Kansenshogaku Zasshi. 2002 Aug;76(8):600-3
references.pmid: 12325318
references.citation: Infect Disord Drug Targets. 2011 Feb;11(1):40-4
references.pmid: 21303340
references.citation: J Antimicrob Chemother. 2012 Aug;67(8):2053-4
references.pmid: 22523307
references.citation: J Infect Chemother. 2010 Dec;16(6):375-82
references.pmid: 20535521